Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study.
Iversen L, Conrad C, Eidsmo L, Costanzo A, Narbutt J, Pinter A, Kingo K, Rivera Diaz R, Kolbinger F, Nanna M, Frueh JA, Jagiello P. Iversen L, et al. Among authors: frueh ja. J Eur Acad Dermatol Venereol. 2023 May;37(5):1004-1016. doi: 10.1111/jdv.18846. Epub 2023 Jan 27. J Eur Acad Dermatol Venereol. 2023. PMID: 36606536 Clinical Trial.
Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification - rationale and design of the randomized, multicenter STEPIn study.
Iversen L, Eidsmo L, Austad J, de Rie M, Osmancevic A, Skov L, Talme T, Bachmann I, van de Kerkhof P, Stahle M, Banerjee R, Oliver J, Fasth AER, Frueh J. Iversen L, et al. J Eur Acad Dermatol Venereol. 2018 Nov;32(11):1930-1939. doi: 10.1111/jdv.14979. Epub 2018 Jul 15. J Eur Acad Dermatol Venereol. 2018. PMID: 29633373 Clinical Trial.
Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks.
von Stebut E, Reich K, Thaçi D, Koenig W, Pinter A, Körber A, Rassaf T, Waisman A, Mani V, Yates D, Frueh J, Sieder C, Melzer N, Mehta NN, Gori T. von Stebut E, et al. J Invest Dermatol. 2019 May;139(5):1054-1062. doi: 10.1016/j.jid.2018.10.042. Epub 2018 Nov 30. J Invest Dermatol. 2019. PMID: 30508547 Free article. Clinical Trial.
Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis.
Blauvelt A, Reich K, Warren RB, Szepietowski JC, Sigurgeirsson B, Tyring SK, Messina I, Bhosekar V, Oliver J, Papavassilis C, Frueh J, Langley RGB. Blauvelt A, et al. Br J Dermatol. 2017 Sep;177(3):879-881. doi: 10.1111/bjd.15656. Epub 2017 Aug 9. Br J Dermatol. 2017. PMID: 28498514 Clinical Trial. No abstract available.
Eltrombopag in patients with chronic immune thrombocytopenia in Asia-Pacific, the Middle East, and Turkey: final analysis of CITE.
Wong RSM, Yavaşoğlu İ, Yassin MA, Tarkun P, Yoon SS, Wei X, Elghandour A, Angchaisuksiri P, Ozcan M, Yang R, Mattar M, Rahman M, Ingles S, Goldbrunner M, Frueh JA, Jang JH. Wong RSM, et al. Among authors: frueh ja. Blood Adv. 2023 Sep 12;7(17):4773-4781. doi: 10.1182/bloodadvances.2022008287. Blood Adv. 2023. PMID: 36103340 Free PMC article.